179 related articles for article (PubMed ID: 10219454)
1. Oxaliplatin in ovarian cancer.
Sessa C; ten Bokkel Huinink WW; du Bois A
Ann Oncol; 1999; 10 Suppl 1():55-7. PubMed ID: 10219454
[TBL] [Abstract][Full Text] [Related]
2. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
Chollet P; Bensmaïne MA; Brienza S; Deloche C; Curé H; Caillet H; Cvitkovic E
Ann Oncol; 1996 Dec; 7(10):1065-70. PubMed ID: 9037366
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
Bleiberg H
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
[TBL] [Abstract][Full Text] [Related]
4. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ
Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460
[TBL] [Abstract][Full Text] [Related]
7. [Oxaliplatin: the first DACH platinum in clinical practice].
Soulié P; Raymond E; Brienza S; Cvitkovic E
Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
[TBL] [Abstract][Full Text] [Related]
8. New developments and approaches in the platinum arena.
Judson I; Kelland LR
Drugs; 2000; 59 Suppl 4():29-36; discussion 37-8. PubMed ID: 10864228
[TBL] [Abstract][Full Text] [Related]
9. [Oxaliplatin and ovarian cancer].
Dieras V; Girre V; Guilhaume MN; Laurence V; Mignot L
Bull Cancer; 2006 Feb; 93 Suppl 1():S35-9. PubMed ID: 16483943
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.
Germann N; Brienza S; Rotarski M; Emile JF; Di Palma M; Musset M; Reynes M; Soulié P; Cvitkovic E; Misset JL
Ann Oncol; 1999 Mar; 10(3):351-4. PubMed ID: 10355582
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
Garg MB; Ackland SP
Cancer Chemother Pharmacol; 2011 Apr; 67(4):963-6. PubMed ID: 20976600
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.
Tashiro T; Kawada Y; Sakurai Y; Kidani Y
Biomed Pharmacother; 1989; 43(4):251-60. PubMed ID: 2790145
[TBL] [Abstract][Full Text] [Related]
14. Ongoing and unsaid on oxaliplatin: the hope.
Cvitkovic E
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):8-11. PubMed ID: 9647613
[TBL] [Abstract][Full Text] [Related]
15. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin.
Lila AS; Kiwada H; Ishida T
Biol Pharm Bull; 2014; 37(2):206-11. PubMed ID: 24492717
[TBL] [Abstract][Full Text] [Related]
16. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of oxaliplatin in urothelial cancer.
Winquist E; Vokes E; Moore MJ; Schumm LP; Hoving K; Stadler WM
Urol Oncol; 2005; 23(3):150-4. PubMed ID: 15907713
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
20. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
Machover D; Diaz-Rubio E; de Gramont A; Schilf A; Gastiaburu JJ; Brienza S; Itzhaki M; Metzger G; N'Daw D; Vignoud J; Abad A; Francois E; Gamelin E; Marty M; Sastre J; Seitz JF; Ychou M
Ann Oncol; 1996 Jan; 7(1):95-8. PubMed ID: 9081400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
